Nano Dimension Ltd. 8-K

What Happened
Nano Dimension Ltd. announced on June 15, 2026 that it entered into a non-binding term sheet with Infinite Epigenetics, Inc. for a proposed business combination. Under the term sheet (subject to a Definitive Agreement), Nano or a successor public company would acquire all issued and outstanding equity of Infinite in exchange for Nano ordinary shares (or ADSs), with post-transaction ownership determined on a fully diluted basis using agreed valuations. Infinite’s valuation is set at $890 million (less a Premium), and Nano’s valuation is equal to 100% of Nano’s actual Net Cash at closing plus a 20% premium of that amount, plus an agreed valuation for Essemtec (estimated at $20 million) and other remaining assets. Nano shareholders are expected to retain a meaningful minority stake. The term sheet also addresses board composition (seven directors: Infinite may name four, or five if Infinite holds >55% post-transaction), a 30-day exclusivity period, and reimbursement of certain Infinite expenses (up to $3 million) if a Definitive Agreement is not executed by the EGM Date under specified conditions. Nano filed the term sheet, a press release, an investor presentation and a call transcript as exhibits to the Form 8‑K.

Key Details

• Date: Term sheet executed June 15, 2026; materials (press release, presentation, transcript) furnished as exhibits.
• Valuation: Infinite valued at $890 million (less Premium); Nano valued as Net Cash + 20% premium + Essemtec (est. $20M) and other assets.
• Governance: Post-closing board of seven directors; Infinite may designate 4 members (5 if Infinite owns >55% fully diluted).
• Other terms: 30-day exclusivity; Nano may reimburse Infinite up to $3 million in documented legal/accounting expenses if the Definitive Agreement is not executed by the EGM Date and certain conditions are met.

Why It Matters
This term sheet outlines a potential merger/acquisition that could materially change Nano Dimension’s business profile, ownership mix and board control. The transaction uses specific, itemized valuation mechanics (Net Cash plus a 20% premium and estimated asset values) rather than a simple share-for-share swap, which will affect dilution and post‑deal ownership percentages for current Nano shareholders. The 30‑day exclusivity and possible $3 million expense reimbursement are important near-term negotiation terms; however, the deal is non-binding until definitive agreements are executed. Investors should watch for a Definitive Agreement, shareholder approvals (including the referenced EGM), and additional financial details that will quantify dilution, timing and strategic impact.